Full-Time

Vice President

Revenue Cycle Management

Posted on 3/26/2025

iRhythm Technologies

iRhythm Technologies

1,001-5,000 employees

Advanced cardiac monitoring solutions provider

Compensation Overview

$246k - $320k/yr

Expert

Remote in USA

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a iRhythm Technologies referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • BA degree in business, finance or management, graduate degree preferred
  • 15+ years Relevant experience leading teams focused on reimbursement, claims processing and collections within healthcare services
  • Strong understanding of payer policies, claim adjudication and financial management
  • Proven experience leading and transforming in-house and vendor-supported revenue cycle operations
  • Exceptional leadership and team-building skills, with a track record of building trust and improving engagement through change within a high-growth environment
  • Demonstrated ability to work effectively across multiple disciplines on projects driving change across organizations
  • Excellent process and project management skills required including the ability to manage a significant volume of highly complex projects with exercise of good triage and judgment skills
  • Data-driven decision-making ability with advanced analytical and problem-solving skills, demonstrated understanding of cost and ROI management
  • Excellent communication and negotiation skills, capable of influencing internal and external stakeholders
Responsibilities
  • Develop and execute a comprehensive revenue cycle strategy to improve collections while simultaneously improving the patient experience and lowering cost-to-collect
  • Oversee the integration of people, processes and technology to optimize revenue cycle outcomes
  • Define and monitor key performance indicators, size opportunities and prioritize and execute actions to deliver sustainable improvements
  • Provide financial insights and recommendations to support strategic decision-making
  • Collaborate with stakeholders at all levels to ensure successful implementation of change and continuous improvement, as well as connect operational changes with predictions of financial outcomes
  • Implement a robust framework for monitoring vendor performance and driving corrective actions and contract revisions as-needed for driving long-term success, while also bringing creative thinking to options on near-term solutions and risk-mitigation
  • Prioritize data accessibility to identify trends in denials, bad debt and overall revenue cycle performance, developing targeted solutions to drive continuous improvement
  • Develop and execute a talent inventory for the organization, ensure we have a strong management bench and development plans to prioritize a high performing, engaged team
  • Communicate with internal and external groups on recommended strategies; articulate the 'big picture' impact of industry trends and incorporate best practices to continuously improve process and results

iRhythm Technologies specializes in cardiac monitoring solutions, primarily through its product, the Zio Patch. This wearable device allows for up to 14 days of continuous heart rhythm tracking, enabling healthcare providers to detect irregular heart rhythms that shorter monitoring periods might miss. The Zio Patch is particularly useful for patients who suspect heart issues, as it allows them to monitor their heart activity without frequent visits to the doctor, which is especially important in the current telehealth environment. iRhythm serves both patients and healthcare providers, selling the Zio Patch and offering data analysis services to interpret the collected heart data. Unlike many competitors, iRhythm focuses specifically on extended ambulatory monitoring, providing a comprehensive view of cardiac health. The company's goal is to enhance patient outcomes and improve healthcare workflows through advanced monitoring technology.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2006

Simplify Jobs

Simplify's Take

What believers are saying

  • iRhythm's expansion into Europe and Japan opens new market opportunities.
  • The wearable medical device market is growing at a 23.1% CAGR until 2030.
  • Integration with EHRs streamlines data sharing and improves patient care.

What critics are saying

  • Increased competition from AI-driven startups threatens iRhythm's market share.
  • FDA warning letter may lead to increased regulatory scrutiny.
  • Shareholder investigation for alleged securities fraud could have legal repercussions.

What makes iRhythm Technologies unique

  • Zio Patch offers up to 14 days of uninterrupted cardiac monitoring.
  • iRhythm integrates AI for predictive analytics in cardiac monitoring.
  • Zio Patch is the smallest and least conspicuous cardiac arrhythmia diagnostic device.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Mental Health Support

Hybrid Work Options

Pet Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

2%
ETF Daily News
Mar 26th, 2025
Cibc World Markets Corp Invests $264,000 in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Cibc World Markets Corp invests $264,000 in iRhythm Technologies, Inc. (NASDAQ:IRTC).

Investing.com
Feb 28th, 2025
iRhythm technologies' CBO and CLO Murphy sells $1.79 million in stock

Additionally, iRhythm is expanding internationally, with early launches in Europe and plans to enter the Japanese market in mid-2025.

Yahoo Finance
Jan 13th, 2025
Irhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights And Business Update At The 43Rd Annual J.P. Morgan Healthcare Conference

iRhythmSAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 43rd Annual J.P. Morgan Healthcare Conference.Recent Operational Highlights and Financial OutlookAnticipate full year 2024 revenue slightly above high end of previously stated guidance range of $587.5 million provided in October 2024Record quarter of new account openings for both Zio monitor and Zio AT during the fourth quarter 2024 as well as strong volume contributions from large national accountsLaunched first four health care systems on Epic Aura during the fourth quarter 2024 with broad commercial roll out for Epic health systems across the U.S. beginning in 2025Initiated Zio monitor shipments for home enrollment patients during the fourth quarter 2024Five studies presented at the American Heart Association highlight Zio Monitor’s high patient satisfaction, engagement and compliance with the patient MyZio app and digital tools, health economic impact of early arrhythmia detection in type 2 diabetes and respiratory disease, and AI insights on sleep and activity patterns 1Expect revenue for the full year 2025 of approximately $675 million to $685 million“This past year was a period of significant growth and transformation for iRhythm,” said Quentin Blackford, iRhythm’s President and CEO. “In our core U.S

MarketBeat
Nov 26th, 2024
Dynamic Technology Lab Private Ltd Invests $1.50 Million in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Dynamic Technology Lab Private Ltd invests $1.50 million in iRhythm Technologies, Inc. (NASDAQ:IRTC).

MPO Magazine
Oct 22nd, 2024
iRhythm Earns FDA Nod for Zio AT After Warning Letter

The letter accused iRhythm of violating Federal Food, Drug, and Cosmetic Act rules about labeling, medical device reporting, and quality systems.

INACTIVE